BioPharma Dive April 8, 2024
The results were the second time Novo Nordisk has shown its weight loss treatment can help with the condition. This time, the study involved participants who had diabetes as well as obesity.
Dive Brief:
- Novo Nordisk’s weight loss drug Wegovy helped people with obesity, diabetes and heart failure have fewer cardiovascular symptoms like fatigue and breathlessness, according to clinical trial results detailed Saturday at the annual American College of Cardiology conference in Atlanta.
- The findings follow another trial Novo conducted in people with obesity and heart failure but not diabetes. That study similarly found that weight loss spurred by Wegovy helped improve symptoms.
- Together, the data may help Novo build a case for expanding Wegovy’s use with regulators and...
Today's Sponsors
Today's Sponsor